A Thorough Synthesis of Phage Therapy Unit Activity in Poland-Its History, Milestones and International Recognition

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2022 Jun 24

PMID 35746642

Authors

Maciej Zaczek

Andrzej Gorski

Beata Weber-Dabrowska

Slawomir Letkiewicz

Wojciech Fortuna

Pawel Rogoz

Edyta Pasternak

Ryszard Miedzybrodzki

Affiliations

Soon will be listed here.

Abstract

The year 2020 marked 15 years of the Phage Therapy Unit in Poland, the inception of which took place just one year after Poland's accession to the European Union (2004). At first sight, it is hard to find any connection between these two events, but in fact joining the European Union entailed the need to adapt the regulatory provisions concerning experimental treatment in humans to those that were in force in the European Union. These changes were a solid foundation for the first phage therapy center in the European Union to start its activity. As the number of centers conducting phage therapy in Europe and in the world constantly and rapidly grows, we want to grasp the opportunity to take a closer look at the over 15-year operation of our site by analyzing its origins, legal aspects at the local and international levels and the impressive number and diversity of cases that have been investigated and treated during this time. This article is a continuation of our work published in 2020 summarizing a 100-year history of the development of phage research in Poland.

Citing Articles

Perception of phage therapy and research across selected professional and social groups in Poland.

Zaczek M, Zielinski M, Gorski A, Weber-Dabrowska B, Miedzybrodzki R Front Public Health. 2025; 13:1490737.

PMID: 40051517 PMC: 11884262. DOI: 10.3389/fpubh.2025.1490737.

Bacteriophage therapy for multidrug-resistant infections: current technologies and therapeutic approaches.

Kim M, Suh G, Cullen G, Perez Rodriguez S, Dharmaraj T, Chang T J Clin Invest. 2025; 135(5).

PMID: 40026251 PMC: 11870740. DOI: 10.1172/JCI187996.

When synthetic biology meets medicine.

Feng Y, Su C, Mao G, Sun B, Cai Y, Dai J Life Med. 2025; 3(1):lnae010.

PMID: 39872399 PMC: 11749639. DOI: 10.1093/lifemedi/lnae010.

Probiotic biofilm modified scaffolds for facilitating osteomyelitis treatment through sustained release of bacteriophage and regulated macrophage polarization.

Su J, Wu Y, Wang Z, Zhang D, Yang X, Zhao Y Mater Today Bio. 2025; 30:101444.

PMID: 39866782 PMC: 11764121. DOI: 10.1016/j.mtbio.2025.101444.

The Appearance of Antiphage Antibodies in Sera of Patients Treated with Phages.

Lusiak-Szelachowska M, Weber-Dabrowska B, Zaczek M, Miedzybrodzki R, Gorski A Antibiotics (Basel). 2025; 14(1.

PMID: 39858371 PMC: 11759190. DOI: 10.3390/antibiotics14010087.

References

Verbeken G, Pirnay J . European regulatory aspects of phage therapy: magistral phage preparations. Curr Opin Virol. 2021; 52:24-29. DOI: 10.1016/j.coviro.2021.11.005. View

Zaluga E . [Skin reactions to antigens of propionibacterium acnes in patients with acne vulgaris treated with autovaccine]. Ann Acad Med Stetin. 1998; 44:65-85. View

SLOPEK S, Weber-Dabrowska B, Dabrowski M, KUCHAREWICZ-KRUKOWSKA A . Results of bacteriophage treatment of suppurative bacterial infections in the years 1981-1986. Arch Immunol Ther Exp (Warsz). 1987; 35(5):569-83. View

Crico C, Sanchini V, Casali P, Pravettoni G . Evaluating the effectiveness of clinical ethics committees: a systematic review. Med Health Care Philos. 2020; 24(1):135-151. PMC: 7910230. DOI: 10.1007/s11019-020-09986-9. View

Letkiewicz S, Miedzybrodzki R, Fortuna W, Weber-Dabrowska B, Gorski A . Eradication of Enterococcus faecalis by phage therapy in chronic bacterial prostatitis--case report. Folia Microbiol (Praha). 2009; 54(5):457-61. DOI: 10.1007/s12223-009-0064-z. View

Letkiewicz S, Lusiak-Szelachowska M, Miedzybrodzki R, Zaczek M, Weber-Dabrowska B, Gorski A . Low Immunogenicity of Intravesical Phage Therapy for Urogenitary Tract Infections. Antibiotics (Basel). 2021; 10(6). PMC: 8225094. DOI: 10.3390/antibiotics10060627. View

SLOPEK S, DURLAKOWA I, Weber-Dabrowska B, Dabrowski M, KUCHAREWICZ-KRUKOWSKA A . Results of bacteriophage treatment of suppurative bacterial infections. III. Detailed evaluation of the results obtained in further 150 cases. Arch Immunol Ther Exp (Warsz). 1984; 32(3):317-35. View

Gorski A, Bollyky P, Przybylski M, Borysowski J, Miedzybrodzki R, Jonczyk-Matysiak E . Perspectives of Phage Therapy in Non-bacterial Infections. Front Microbiol. 2019; 9:3306. PMC: 6333649. DOI: 10.3389/fmicb.2018.03306. View

Gorski A, Borysowski J, Miedzybrodzki R . The contribution of phage therapy to medical knowledge. J Glob Antimicrob Resist. 2022; 28:238-240. DOI: 10.1016/j.jgar.2022.01.019. View

10.

SLOPEK S, DURLAKOWA I, Weber-Dabrowska B, KUCHAREWICZ-KRUKOWSKA A, Dabrowski M, Bisikiewicz R . Results of bacteriophage treatment of suppurative bacterial infections. II. Detailed evaluation of the results. Arch Immunol Ther Exp (Warsz). 1983; 31(3):293-327. View

11.

Du Toit A . Remember the phages. Nat Rev Microbiol. 2022; 20(5):254. DOI: 10.1038/s41579-022-00718-9. View

12.

Miedzybrodzki R, Fortuna W, Weber-Dabrowska B, Gorski A . A retrospective analysis of changes in inflammatory markers in patients treated with bacterial viruses. Clin Exp Med. 2009; 9(4):303-12. DOI: 10.1007/s10238-009-0044-2. View

13.

RUBISZ-BRZEZINSKA J, Brzezinska-Wcislo L, Kasprowicz A . [Clinical evaluation of serious forms of acne treated with autovaccine]. Med Dosw Mikrobiol. 1994; 46(1-2 Suppl):35-42. View

14.

Gorski A, Jonczyk-Matysiak E, Lusiak-Szelachowska M, Miedzybrodzki R, Weber-Dabrowska B, Borysowski J . Phage Therapy in Prostatitis: Recent Prospects. Front Microbiol. 2018; 9:1434. PMC: 6034095. DOI: 10.3389/fmicb.2018.01434. View

15.

SLOPEK S, KUCHAREWICZ-KRUKOWSKA A, Weber-Dabrowska B, Dabrowski M . Results of bacteriophage treatment of suppurative bacterial infections. V. Evaluation of the results obtained in children. Arch Immunol Ther Exp (Warsz). 1985; 33(2):241-59. View

16.

Borysowski J, Gorski A . Compassionate use of unauthorized drugs: Legal regulations and ethical challenges. Eur J Intern Med. 2019; 65:12-16. DOI: 10.1016/j.ejim.2019.04.008. View

17.

Chen P, Liu Z, Tan X, Wang H, Liang Y, Kong Y . Bacteriophage therapy for empyema caused by carbapenem-resistant Pseudomonas aeruginosa. Biosci Trends. 2022; 16(2):158-162. DOI: 10.5582/bst.2022.01147. View

18.

Zaczek M, Weber-Dabrowska B, Miedzybrodzki R, Lusiak-Szelachowska M, Gorski A . Phage Therapy in Poland - a Centennial Journey to the First Ethically Approved Treatment Facility in Europe. Front Microbiol. 2020; 11:1056. PMC: 7291835. DOI: 10.3389/fmicb.2020.01056. View

19.

Thompson T . The staggering death toll of drug-resistant bacteria. Nature. 2022; . DOI: 10.1038/d41586-022-00228-x. View

20.

Safari Z, Sadeghizadeh M, Asgaritarghi G, Bardania H, Sadeghizadeh D, Soudi S . M13 phage coated surface elicits an anti-inflammatory response in BALB/c and C57BL/6 peritoneal macrophages. Int Immunopharmacol. 2022; 107:108654. DOI: 10.1016/j.intimp.2022.108654. View